KRAS and non-small cell lung carcinoma: Given the changing landscape of advanced NSCLC treatment with first-line chemo-immunotherapy becoming standard of care and the approval of KRAS G12C direct inhibitors for that subset of KRAS-mutated NSCLC, the limited clinical activity and the toxicity observed, this study was closed and did not accrue to the dose expansion cohorts.